RECORD // Company
Karyopharm Therapeutics Inc.
Built 2026-11-22T00:37:31Z from public sources · JSON · Open the company profile
ASK THE RECORDS
Ask
COMPANY
Records for this company (2 joined by official identifier)
Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.
Gleif lei (1)
- Karyopharm Therapeutics Inc. · legal entity in this company's GLEIF ownership tree (LEI 549300J1VANRCNTYST87)
SEC EDGAR (1)
- Karyopharm Therapeutics Inc. · the SEC registrant record of this company
Matched by name only, not merged (5)
These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).
- Karyopharm Therapeutics Inc · Ctgov · same registered legal name as 'Karyopharm Therapeutics Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
- Karyopharm Therapeutics Inc. · East licences · same registered legal name as 'Karyopharm Therapeutics Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
- KARYOPHARM THERAPEUTICS INC · Epa echo · same registered legal name as 'Karyopharm Therapeutics Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
- KARYOPHARM THERAPEUTICS INC., (lobbying via BGR GOVERNMENT AFFAIRS) · LDA lobbying · same registered legal name as 'Karyopharm Therapeutics Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
- KARYOPHARM THERAPEUTICS INC. · Ny corps · same registered legal name as 'Karyopharm Therapeutics Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
4 VALUES · 10-Q · EACH LINKS TO ITS FILING
Latest quarter
Latest report: 10-Q for the period ended 2026-06-30, filed 2026-08-13 · accession 0001193125-26-347906
| Item | Value | Period | Form | Filed | Accession | Report | |
|---|---|---|---|---|---|---|---|
| Revenue | $33,432,000 | 3 months ended 2026-06-30 | 10-Q | 2026-08-13 | 0001193125-26-347906 | 2026-11-22 00:37 UTC | Report an error |
| Net income (loss) | $-67,023,000 | 3 months ended 2026-06-30 | 10-Q | 2026-08-13 | 0001193125-26-347906 | 2026-11-22 00:37 UTC | Report an error |
| Interest expense | $13,144,000 | 3 months ended 2026-06-30 | 10-Q | 2026-08-13 | 0001193125-26-347906 | 2026-11-22 00:37 UTC | Report an error |
| Cash and cash equivalents | $54,980,000 | at 2026-06-30 | 10-Q | 2026-08-13 | 0001193125-26-347906 | 2026-11-22 00:37 UTC | Report an error |
Negative as reported in the filing.
Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.
IDS
Identifiers
- SEC CIK
- 0001503802
- Ticker
- KPTIQ
- EIN
- 263931704
- CUSIP
- 48576U205
- Record ID
- sx:sec:0001503802
OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA
Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
31 FACTS · EACH LINKS TO ITS FILING
Facts
| Fact | Value | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 00:37 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 00:37 UTC | Report an error |
| State of incorporation | DE | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 00:37 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 00:37 UTC | Report an error |
| Business address | 85 WELLS AVENUE, SECOND FLOOR, NEWTON, MA, 02459 | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 00:37 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 00:37 UTC | Report an error |
| Revenue (fiscal year ended 2025-12-31) | $146,067,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | 2026-11-22 00:37 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | $-196,039,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | 2026-11-22 00:37 UTC | Report an error |
| Total assets (at 2025-12-31) | $108,416,000 | 2025-12-31 | 10-K, XBRL Assets | 2026-11-22 00:37 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $-292,926,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | 2026-11-22 00:37 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $60,540,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | 2026-11-22 00:37 UTC | Report an error |
| Operating cash flow (fiscal year ended 2025-12-31) | $-75,369,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | 2026-11-22 00:37 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $0 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | 2026-11-22 00:37 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $6,712,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | 2026-11-22 00:37 UTC | Report an error |
| Form D total offering amount (D filed 2022-12-08) | $165,000,003 | 2022-12-08 | D | 2026-11-22 00:37 UTC | Report an error |
| Form D total amount sold (D filed 2022-12-08) | $165,000,003 | 2022-12-08 | D | 2026-11-22 00:37 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2022-12-08 | D | 2026-11-22 00:37 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2022-12-08 | D | 2026-11-22 00:37 UTC | Report an error |
| Form D date of first sale | 2022-12-07 | 2022-12-08 | D | 2026-11-22 00:37 UTC | Report an error |
| Plan (pension, plan no. 001) | KARYOPHARM THERAPEUTICS INC. 401(K) PLAN: 457 participants, assets $64,093,251 | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | 2026-11-22 00:37 UTC | Report an error |
| Plan (welfare, plan no. 501) | KARYOPHARM THERAPEUTICS INC. BENEFITS PLAN: 243 participants | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | 2026-11-22 00:37 UTC | Report an error |
| Largest institutional holder #1 (13F as filed): RA CAPITAL MANAGEMENT, L.P. | $18,732,549 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 00:37 UTC | Report an error |
| Largest institutional holder #2 (13F as filed): ADAGE CAPITAL PARTNERS GP, L.L.C. | $14,863,316 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 00:37 UTC | Report an error |
| Largest institutional holder #3 (13F as filed): ACORN CAPITAL ADVISORS, LLC | $14,831,964 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 00:37 UTC | Report an error |
| Largest institutional holder #4 (13F as filed): GOLDMAN SACHS GROUP INC | $13,918,908 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 00:37 UTC | Report an error |
| Largest institutional holder #5 (13F as filed): BlackRock, Inc. | $13,861,666 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 00:37 UTC | Report an error |
| Largest institutional holder #6 (13F as filed): Kalehua Capital Management LLC | $13,397,484 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 00:37 UTC | Report an error |
| Largest institutional holder #7 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC | $9,369,225 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 00:37 UTC | Report an error |
| Largest institutional holder #8 (13F as filed): Catalio Capital Management, LP | $9,192,153 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 00:37 UTC | Report an error |
| Largest institutional holder #9 (13F as filed): Avidity Partners Management LP | $9,032,238 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 00:37 UTC | Report an error |
| Largest institutional holder #10 (13F as filed): TWO SIGMA INVESTMENTS, LP | $6,792,729 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 00:37 UTC | Report an error |
EVERY DATED RECORD, NEWEST FIRST
Timeline
- 2026-11-13 Filing NT 10-Q filed
- 2026-11-05 Filing 8-K filed: Item 3.01 delisting notice
- 2026-11-03 Filing 8-K filed: Item 1.01 material agreement; Item 1.03 bankruptcy; Item 2.03 new financial obligation; Item 2.04; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-11-02 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-22 Filing 8-K filed: Item 8.01 other event
- 2026-10-14 Filing 8-K filed: Item 8.01 other event
- 2026-10-01 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-09-18 Filing 8-K filed: Item 3.03 rights of holders modified; Item 5.03 charter or bylaw amendment; Item 9.01 exhibits
- 2026-09-11 Filing 8-K filed: Item 1.01 material agreement; Item 2.04; Item 3.02 unregistered equity sale; Item 8.01 other event; Item 9.01 exhibits
- 2026-08-31 Filing 8-K filed: Item 8.01 other event
- 2026-08-13 Filing 10-Q filed
- 2026-08-13 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-31 Filing 8-K filed: Item 8.01 other event
- 2026-07-17 Filing 8-K filed: Item 5.02 officer or director change
- 2026-06-10 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 501)
- 2026-05-28 Filing 8-K filed: Item 5.02 officer or director change; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-05-27 Filing S-8 filed
- 2026-05-27 Filing S-8 filed
- 2026-05-14 Filing EFFECT filed
- 2026-05-14 Filing EFFECT filed
- 2026-05-14 Filing 10-Q filed
- 2026-05-14 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-05-12 Filing CORRESP filed
- 2026-05-12 Filing CORRESP filed
- 2026-05-07 Filing UPLOAD filed
- 2026-05-07 Filing UPLOAD filed
- 2026-05-04 Filing S-3 filed
- 2015-12-01 Record plan effective date: KARYOPHARM THERAPEUTICS INC. BENEFITS PLAN
- 2011-01-01 Record plan effective date: KARYOPHARM THERAPEUTICS INC. 401(K) PLAN
WHAT IS NOT HERE
Gaps
- Court records: not covered yet (expected 11-19).
- No H-1B LCA filed under EIN 263931704 in FY2026 Q3
- H-1B LCAs only (H-1B1 and E-3 excluded); one fiscal quarter (FY2026 Q3) only, earlier quarters not loaded
- Plan year 2025 only (EFAST2 'Latest' file); earlier years not loaded
- Administrator, signer and preparer names are not kept; sponsor (employer) name only
- Total assets shown only where the plan attached Schedule H (small plans file Schedule I or none)
- Participants: counts at the beginning and at the end of the plan year (end of year includes active, retired and separated participants)
- No Form 990 found for EIN 263931704
- USAspending: no recipient whose SAM legal name and address match this SEC filer
SOURCES AND LICENSE
Sources
- SEC EDGAR: checked · 2026-11-22T00:37:31Z
- DOL OFLC LCA Disclosure Data: checked, nothing found · 2026-11-22T00:37:32Z
- DOL EBSA Form 5500 public datasets: checked · 2026-11-22T00:37:32Z
- Propublica 990: checked, nothing found · 2026-11-22T00:37:32Z
- SEC 13F holdings: checked · 2026-11-22T00:37:32Z
- USAspending: checked, nothing found · 2026-11-22T00:37:35Z
CC BY 4.0 -- credit Seraphix Systems.
API
Use this record
Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.